Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Allerex is an ophthalmic small molecule combination drug developed and marketed by Lin-Kabs Pharmaceutical. It is primarily indicated for the symptomatic relief of allergic conjunctivitis and minor ocular irritations. The formulation consists of antazoline hydrochloride, a histamine H1 receptor antagonist, and naphazoline hydrochloride, a sympathomimetic alpha-adrenergic agonist. Antazoline works by blocking H1 receptors, thereby reducing allergic symptoms such as itching and swelling. Naphazoline acts as a vasoconstrictor by stimulating alpha-adrenergic receptors on conjunctival blood vessels, which reduces redness and congestion. Allerex is administered topically as an eye drop and is approved for use in managing various inflammatory eye disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on antazoline + naphazoline.